Stock listing

Shanghai:688177 Bio-Thera Solutions, Ltd. (百奥泰) 股价

Follow Bio-Thera Solutions, Ltd. into a list and get an email when it puts out news.

Share price · SSE:688177

¥14.16 CNY -0.87 (-5.8%)

Close on Nov 20, 2026

Past year -44.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥14.15 – ¥14.69 CNYNov 20, 2026
Volume
2.98M sharesNov 20, 2026
Market cap
¥5.86B CNYAt the close on Nov 20, 2026 · price × 414.1M shares outstanding
52-week range
¥14.15 – ¥26.33 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥68.64M CNYMedian day 3.19M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Bio-Thera Solutions, Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:688177 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥14.16-0.87-5.8%¥14.69¥14.69¥14.152,977,983
¥15.03-0.59-3.8%¥15.73¥15.79¥15.022,542,438
¥15.62-0.54-3.3%¥16.10¥16.35¥15.533,471,826
¥16.16-0.56-3.3%¥16.55¥16.75¥16.012,677,568
¥16.72-0.59-3.4%¥17.35¥17.40¥16.612,035,224
¥17.31-0.35-2.0%¥17.66¥17.70¥17.312,429,102
¥17.66+0.13+0.7%¥17.61¥17.73¥17.401,564,935
¥17.53-0.11-0.6%¥17.88¥18.03¥17.531,522,984
¥17.64-0.13-0.7%¥17.98¥18.11¥17.511,928,892
¥17.77-0.05-0.3%¥17.57¥18.07¥17.363,314,094
¥17.82+0.51+2.9%¥17.31¥17.99¥17.313,096,081
¥17.31+0.74+4.5%¥16.51¥17.55¥16.354,262,133
¥16.57-0.25-1.5%¥16.89¥16.89¥16.323,402,348
¥16.82+0.46+2.8%¥16.37¥17.00¥16.073,475,183
¥16.36-0.57-3.4%¥16.65¥17.68¥16.264,184,419
¥16.93-0.43-2.5%¥17.37¥17.43¥16.603,343,422
¥17.36+0.08+0.5%¥17.55¥17.80¥16.892,908,470
¥17.28-0.73-4.1%¥18.20¥18.29¥17.282,493,119
¥18.01-0.10-0.6%¥18.01¥18.39¥17.832,599,894
¥18.11+0.77+4.4%¥17.21¥18.20¥16.763,823,585
¥17.34-0.45-2.5%¥18.05¥18.15¥17.272,557,006
¥17.79-0.10-0.6%¥18.10¥18.48¥17.752,926,401
¥17.89+0.70+4.1%¥17.30¥17.91¥16.913,488,053
¥17.19+0.26+1.5%¥17.00¥17.47¥16.643,227,266
¥16.93-0.16-0.9%¥17.25¥17.94¥16.793,730,956
¥17.09-0.34-2.0%¥17.22¥17.93¥17.004,336,998
¥17.43-0.48-2.7%¥17.77¥17.98¥17.202,919,829
¥17.91-0.80-4.3%¥18.60¥18.63¥17.553,666,043
¥18.71-0.59-3.1%¥19.50¥19.52¥18.683,341,419
¥19.30+0.07+0.4%¥19.06¥19.84¥18.465,585,575
¥19.23-1.80-8.6%¥20.68¥21.60¥19.105,485,175
¥21.03+0.82+4.1%¥20.01¥21.34¥20.014,997,608
¥20.21-0.44-2.1%¥20.45¥20.87¥20.004,488,138
¥20.65-0.18-0.9%¥20.80¥21.36¥20.214,947,856
¥20.83-0.44-2.1%¥21.51¥21.68¥20.777,173,494
¥21.27+0.17+0.8%¥21.00¥21.93¥20.8110,792,189
¥21.10+1.74+9.0%¥19.36¥21.34¥19.0611,476,537
¥19.36+2.16+12.6%¥17.31¥19.55¥17.209,841,286
¥17.20+0.46+2.7%¥16.77¥17.42¥16.772,975,913
¥16.74+0.15+0.9%¥16.60¥16.96¥16.411,891,200
¥16.59+0.13+0.8%¥16.50¥16.63¥16.271,537,424
¥16.46-0.36-2.1%¥16.80¥16.85¥16.411,601,982
¥16.82+0.58+3.6%¥16.30¥16.89¥16.032,724,874
¥16.24-0.53-3.2%¥16.81¥16.84¥16.012,818,767
¥16.77-0.30-1.8%¥17.01¥17.09¥16.591,741,301
¥17.07-0.34-2.0%¥17.40¥17.40¥17.011,856,320
¥17.41+0.14+0.8%¥17.54¥17.55¥17.062,341,364
¥17.27-0.21-1.2%¥17.50¥17.62¥17.231,938,659
¥17.48-0.31-1.7%¥17.84¥17.95¥17.422,835,834
¥17.79+0.14+0.8%¥17.67¥17.90¥17.512,313,675
¥17.65-0.16-0.9%¥17.81¥17.87¥17.352,978,402
¥17.81-0.40-2.2%¥18.17¥18.30¥17.694,606,051
¥18.21-0.42-2.3%¥18.63¥18.63¥18.093,160,230
¥18.63-0.11-0.6%¥18.60¥19.04¥18.393,542,970
¥18.74-0.66-3.4%¥19.39¥19.39¥18.385,028,825
¥19.40-0.74-3.7%¥19.99¥20.98¥19.293,883,621
¥20.14+0.17+0.9%¥19.97¥20.23¥19.572,955,815
¥19.97-0.74-3.6%¥20.60¥20.88¥19.803,459,189
¥20.71-1.04-4.8%¥21.32¥21.75¥20.614,869,704
¥21.75+1.18+5.7%¥21.58¥22.35¥20.888,087,524
Ticker
Shanghai:688177
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Shanghai
Currency
CNY

What changed lately

Latest news

All Bio-Thera Solutions, Ltd. news

Bio-Thera Solutions, Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
50 in the last 12 months · 107 in all · newest Nov 17, 2026 · oldest 2023

Valuation

EV/sales 5.9× against a median of 26.0×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥6.17B CNY
P/E
Loss
EV/sales
5.9×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
137×
Gross margin
81.0%
Operating margin
−39.2%
Net margin
−42.0%
Debt to equity
14.3×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Bio-Thera Solutions, Ltd. Class A · SSE:688177US$880.1MUS$926.3Mn/a5.9×n/a137×−42.0%14.3×n/a
MoonLake Immunotherapeutics · NASDAQ:MLTXUS$942.1MUS$543.7Mn/an/an/a2.5×n/a0.3×1.32
Savara, Inc. · NASDAQ:SVRAUS$939.9MUS$840.4Mn/an/an/a8.7×n/a0.3×1.42
Metis TechBio Co., Ltd. Class H · HKEX:7666US$918.2MUS$486.7Mn/a222×n/a2.0×−373.2%0.0×n/a
InventisBio, Co., Ltd. Class A · SSE:688382US$899.5MUS$714.3Mn/a67.0×n/a4.6×−533.7%0.0×n/a
InnoCare Pharma Ltd. Class A · SSE:688428US$896.7M−US$209.5M9.3×−0.6×−2.3×0.8×27.1%0.1×n/a
Immatics N.V. · NASDAQ:IMTXUS$878.3MUS$375.4Mn/a7.9×n/a1.8×−534.1%0.0×1.40
Suzhou Ribo Life Science Co. Ltd. Class H · HKEX:6938US$875.5MUS$580.0Mn/a26.0×n/a3.4×−187.2%0.2×n/a
Aktis Oncology, Inc. · NASDAQ:AKTSUS$868.0MUS$385.9Mn/a31.2×n/a1.9×−706.8%0.0×1.21
Latigo Biotherapeutics, Inc. · NASDAQ:LTGOUS$861.9MUS$460.7Mn/an/an/a2.2×n/a0.0×n/a
Pharming Group NV · EURONEXT:PHARMUS$840.1MUS$766.3M34.4×2.0×19.8×2.9×6.3%0.4×n/a
Median of the othersUS$887.5MUS$515.2M21.9×26.0×8.7×2.3×−373.2%0.1×1.36

Forecasts

Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
26.30 CNY · Analysts' mean
EPS, year to Dec 2026
-0.83 · 1 analyst
Revenue, year to Dec 2026
1.28B · 1 analyst

Team and board

OfficerRole
Susan RingdalEVP, Strategic Planning and Global Affairs

Events

QuarterResultsShare move
Q1 2022Apr 29, 2022 · Before open−6.6%
Q4 2021Mar 4, 2022 · Before open−0.8%
Q3 2021Oct 29, 2021+0.5%
Quarter to Jun 30, 2021Aug 27, 2021+8.9%
Quarter to Mar 31, 2021Apr 28, 2021−6.4%
Quarter to Dec 31, 2020Mar 4, 2021 · Before open−1.7%

Open Events

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue935.2M743.2M704.8M455.1M836.6M185.0M700.0K02.01M2.76M
Cost of revenue197.2M229.5M193.3M190.6M35.6M19.9M127.8K722.7K1.92M
Gross profit738.0M513.6M511.5M264.5M801.0M165.1M572.3K01.29M842.0K
Research and development800.2M777.6M768.6M616.4M543.4M562.7M636.5M541.7M236.5M131.5M
Selling, general and administrative273.3M215.5M102.8M153.7M194.4M143.2M32.6M8.94M5.82M4.81M
Operating income-346.3M-496.0M-392.6M-494.6M84.3M-546.6M-1.02B-553.7M-239.1M-143.6M
Depreciation and amortization104.3M89.4M85.2M83.8M72.9M59.0M55.5M49.5M23.0M5.23M
EBITDA-242.0M-406.6M-307.3M-410.8M157.2M-487.7M-969.3M-504.2M-216.1M-138.4M
Interest expense20.1M20.6M10.4M61.9K775.4K3.70M770.0K27.8K00
Income before tax-331.6M-510.3M-394.4M-480.4M91.0M-513.2M-1.02B-553.1M-235.5M-136.6M
Income tax2.13K9.11M
Net income-331.9M-510.3M-394.5M-480.4M81.9M-513.2M-1.02B-553.1M-235.5M-136.6M
Earnings per share, basic-0.80-1.23-0.95-1.160.20-1.24-2.89-1.56-0.67

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents218.6M289.8M164.0M165.9M847.5M283.5M39.1M112.4M33.4M8.42M
Short-term investments90.2M331.0M629.9M602.8M955.8M
Receivables164.7M104.1M148.7M89.8M103.3M55.4M1.11M986.2K11.0M2.25M
Inventory312.4M253.1M231.2M161.9M90.1M45.9M43.6M36.7M7.87M2.14M
Current assets958.6M888.0M1.01B1.16B1.77B1.47B177.8M217.3M120.8M332.2M
Property, plant and equipment693.9M579.4M581.7M425.4M417.9M427.4M300.2M
Total assets2.29B2.21B2.29B2.18B2.62B2.39B1.01B1.02B618.9M708.3M
Accounts payable198.7M199.5M171.5M83.8M45.7M84.8M153.5M99.1M111.4M116.2M
Current liabilities1.37B1.10B725.4M538.5M526.0M385.4M380.5M213.2M271.0M173.3M
Long-term debt374.2M370.4M323.8M3.00M
Total liabilities1.91B1.50B1.07B572.5M530.3M387.6M383.7M219.4M271.4M173.9M
Shareholders' equity376.0M708.1M1.21B1.61B2.09B2.01B630.7M801.3M347.6M534.4M
Shares outstanding414.1M414.1M414.1M414.1M414.1M414.1M354.1M354.1M354.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-82.1M-55.7M-460.9M-412.8M236.3M-358.0M-598.0M-528.2M-236.7M-116.2M
Capital spending-121.7M-126.8M-275.9M-258.8M-77.9M-253.3M-74.8M-317.8M-160.8M-119.2M
Free cash flow-203.9M-182.5M-780.3M-671.6M158.4M-611.3M-672.8M-846.0M-397.5M-235.4M
Cash from investing-245.8M301.8M-1.18B-74.8M-339.3M-145.6M-119.1M
Cash from financing-30.2M26.5M1.78B599.3M933.0M99.0M
Dividends paid-20.4M-20.6M-5.67M-164.5K-553.0K-3.85M-620.6K-620.6K-620.6K
Change in cash-50.1M150.9M169.4M-688.0M563.8M244.2M-73.5M65.4M-283.2M311.4M

Open Financials

Filings

FilingDateTypeFiled with
(688177)"Bio-Thera Solutions, Ltd."Announcement on Change of Accounting FirmNov 17, 2026Management or board changeShanghai Stock Exchange
(688177)"Bio-Thera Solutions, Ltd."Notice on Convening the 4th Extraordinary General Meeting in 2026Nov 17, 2026Meeting noticeShanghai Stock Exchange
(688177)"Bio-Thera Solutions, Ltd."Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026Nov 14, 2026Meeting outcomeShanghai Stock Exchange
(688177)"Bio-Thera Solutions, Ltd."Announcement on Obtaining a Drug Registration Certificate for Ashuli (Golimumab Injection)Nov 6, 2026Operations updateShanghai Stock Exchange
(688177)"Bio-Thera Solutions, Ltd."Announcement on Convening the Q3 2026 Performance BriefingNov 3, 2026Meeting noticeShanghai Stock Exchange
(688177)"Bio-Thera Solutions, Ltd."Announcement on the Latest Business Development of BAT1706 (Bevacizumab)Nov 3, 2026Other filingsShanghai Stock Exchange
(688177)"Bio-Thera Solutions, Ltd."Report for Q3 2026Oct 28, 2026Quarterly reportShanghai Stock Exchange
(688177)"Bio-Thera Solutions, Ltd."Notice on Convening the 3rd Extraordinary General Meeting in 2026Oct 28, 2026Meeting noticeShanghai Stock Exchange
(688177)"Bio-Thera Solutions, Ltd."Announcement on Re-deliberation of Energy Management Agreements and Routine Related Party TransactionsOct 28, 2026Material contractShanghai Stock Exchange
(688177)"Bio-Thera Solutions, Ltd."Announcement on Signing of Energy Management Agreement for Distributed Rooftop PV Power Station between Wholly-owned Subsidiary and Related Party, and Related Party TransactionOct 28, 2026Material contractShanghai Stock Exchange
All 75 filings
FilingDateTypeFiled with
(688177)"Bio-Thera Solutions, Ltd."Announcement on Obtaining the Drug Registration Certificate for BAT2306 (Secukinumab Injection)Oct 23, 2026Operations updateShanghai Stock Exchange
"Bio-Thera Solutions, Ltd."Announcement on Attending the 2026 Collective Reception Day for Investors in Guangdong Jurisdiction and Interim Performance Briefing for Listed Companies in the JurisdictionSep 7, 2026Meeting noticeShanghai Stock Exchange
"Bio-Thera Solutions, Ltd."Announcement on Resignation of the Chief Financial Officer and Designation of the Chairman and the General Manager to Act as the Chief Financial OfficerSep 1, 2026Management or board changeShanghai Stock Exchange
"Bio-Thera Solutions, Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 25, 2026Other filingsShanghai Stock Exchange
"Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for Supplementary Application for Bevacizumab Injection (POBEVCY)Aug 20, 2026Other filingsShanghai Stock Exchange
"Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure Regarding the Progress of Receipt of Milestone Payment under the License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) InjectionJul 29, 2026Other filingsShanghai Stock Exchange
"Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026Jul 28, 2026GuidanceShanghai Stock Exchange
"Bio-Thera Solutions, Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual ReportJun 30, 2026Legal or regulatory actionShanghai Stock Exchange
Announcement on the Status of the EU GMP Inspection at the Yonghe FacilityJun 14, 2026Operations updateShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of BAT2206 (Ustekinumab Injection) by Singapore HSAJun 10, 2026Other filingsShanghai Stock Exchange
Announcement on Obtaining Drug Registration Certificate for ICHALIG®/XICHALIG® (Ustekinumab Injection)May 21, 2026Operations updateShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT8013 for InjectionMay 12, 2026Operations updateShanghai Stock Exchange
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026Apr 30, 2026Meeting outcomeShanghai Stock Exchange
Announcement on Loan Application Business of the Wholly-owned Subsidiary and the Company's Provision of GuaranteeApr 27, 2026FinancingShanghai Stock Exchange
Notice on Convening the 2nd Extraordinary General Meeting in 2026Apr 14, 2026Meeting noticeShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT3306 Combined with BAT8008 for Treatment for Advanced Solid TumorsApr 2, 2026Operations updateShanghai Stock Exchange
Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Progress in Commercialization Agreement with STADA for BAT2506 (Golimumab) InjectionMar 26, 2026Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT8008 Combined with BAT1006 and Trastuzumab of Advanced Solid TumorsMar 6, 2026Operations updateShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Usymro (Ustekinumab Injection) by UK MHRAMar 3, 2026Other filingsShanghai Stock Exchange
Announcement on Preliminary Earnings Estimate for 2025Feb 26, 2026ResultsShanghai Stock Exchange
Announcement on Acceptance of the Marketing Authorization Application for Batopoizumab Injection (BAT4406F)Feb 24, 2026Other filingsShanghai Stock Exchange
Announcement on Marketing Authorization Approval of Gotenfia (Golimumab Injection) by European Medicines Agency (EMA)Feb 12, 2026Operations updateShanghai Stock Exchange
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Feb 6, 2026Meeting outcomeShanghai Stock Exchange
Announcement on Voluntary Disclosure of Execution of a License, Manufacturing, Supply, and Commercialization Agreement with Avalon Pharma Regarding BAT3306 (Pembrolizumab) InjectionFeb 3, 2026Other filingsShanghai Stock Exchange
Announcement on Changing Sponsor RepresentativeFeb 2, 2026Other filingsShanghai Stock Exchange
Announcement on Expected Loss in Performance for 2025Jan 27, 2026ResultsShanghai Stock Exchange
Announcement on Return of Raised Funds Temporarily Used to Supplement Current CapitalJan 22, 2026FinancingShanghai Stock Exchange
Announcement on Signing a Project Construction Work Contract by the Wholly-owned Subsidiary and Related Party and Related Party TransactionsJan 21, 2026Material contractShanghai Stock Exchange
Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization, Production, Supply and Commercialization Agreement with Gedeon Richter Plc. (Richter Gedeon) for BAT2206 (Ustekinumab) InjectionJan 13, 2026Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (Ustekinumab) InjectionJan 9, 2026Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Sandoz AG for BAT1706 (Bevacizumab) InjectionDec 30, 2025Operations updateShanghai Stock Exchange
Announcement on Estimated Daily Related Party Transactions in 2026Dec 29, 2025Other filingsShanghai Stock Exchange
Announcement on Obtaining Government SubsidiesDec 22, 2025Other filingsShanghai Stock Exchange
Announcement on Acceptance of Marketing Authorization Application for Vilacita Monoclonal Antibody Injection (BAT5906)Dec 18, 2025Other filingsShanghai Stock Exchange
Announcement on Convening the Q3 2025 Performance BriefingNov 12, 2025Meeting noticeShanghai Stock Exchange
Report for Q3 2025Oct 28, 2025Quarterly reportShanghai Stock Exchange
Announcement on Voluntary Disclosure of Progress in the Receipt of the Initial Payment from STADA for the Signing of the Licensing and Commercialization Agreement for BAT1806 (Tocilizumab) InjectionOct 17, 2025Other filingsShanghai Stock Exchange
Announcement on the Resignation of Core Technical PersonnelSep 30, 2025Management or board changeShanghai Stock Exchange
Announcement on Completing Industrial and Commercial Change Registration of Registered Address and Amending the Articles of AssociationSep 23, 2025Other filingsShanghai Stock Exchange
Announcement on Attending 2025 Online Collective Reception Day for Investors in Guangdong JurisdictionSep 15, 2025Notification letterShanghai Stock Exchange
Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) InjectionSep 11, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Qletli (Adalimumab Solution for Injection) by UK MHRASep 10, 2025Operations updateShanghai Stock Exchange
Announcement on Convening the Semi-annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2025Sep 5, 2025Other filingsShanghai Stock Exchange
Notice on Convening the 2nd Extraordinary General Meeting in 2025Aug 29, 2025Meeting noticeShanghai Stock Exchange
Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current CapitalAug 20, 2025Other filingsShanghai Stock Exchange
Announcement on Result of Shareholding Reduction by ShareholderAug 19, 2025Other filingsShanghai Stock Exchange
Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Current CapitalAug 18, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT1308 Injection Combined with BAT4706 Injection and BAT8008 for Injection for Treatment of Advanced Solid TumorsAug 7, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (BAT5906)Aug 1, 2025Other filingsShanghai Stock Exchange
Announcement on the Change of Office Address and Contact Information of InvestorsJul 31, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Semi-annual Earnings Preannouncement for 2025Jul 29, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT4406F InjectionJul 21, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Signing Authorization License and Production, Supply and Commercialization Agreement with SteinCares for BAT2406 (Dupilumab) InjectionJun 23, 2025Other filingsShanghai Stock Exchange
Announcement on FDA Approval for BAT2206 (Ustekinumab) Injection in the United StatesMay 23, 2025Other filingsShanghai Stock Exchange
Announcement on Adjusting the Development Strategy of BAT3306 (Pembrolizumab)May 22, 2025Other filingsShanghai Stock Exchange
Announcement on Completing the Term Change and Election of the Board of Directors and Appointment of Senior Management Members, Securities Affairs Representatives, and Head of Internal AuditApr 30, 2025Management or board changeShanghai Stock Exchange
Report for Q1 2025Apr 28, 2025Other filingsShanghai Stock Exchange
Announcement on Share Reduction Plan for ShareholdersApr 23, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT7111 for InjectionApr 21, 2025Other filingsShanghai Stock Exchange
Announcement on Election of Employee Representative Director for the Third Board of DirectorsApr 18, 2025Other filingsShanghai Stock Exchange
Notice on Convening the 2024 Annual General MeetingApr 8, 2025Meeting noticeShanghai Stock Exchange
Announcement on the Latest Development of BAT1806 (Tocilizumab) BusinessApr 1, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Progress of Down-payment Received for Signing Authorization License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) InjectionMar 31, 2025Other filingsShanghai Stock Exchange
Announcement on Resolution of the 18th Meeting of the 2nd Board of SupervisorsMar 21, 2025Other filingsShanghai Stock Exchange
Announcement on Obtaining Acceptance of Application for Marketing Authorization of Golimumab Injection (BAT2506)Mar 13, 2025Other filingsShanghai Stock Exchange

Open Filings

Cap table

Built by 6ix from Bio-Thera Solutions, Ltd. Class A’s releases

Common shares
414,080,000
Fully diluted
414,080,000

Fully diluted

LineShares
Common shares414,080,000

Share count over time

CountShares
Nov 22, 2026414,080,000

Open Cap table

Shareholders

HolderSharesValueChangeAs of
Vanguard Total International Stock Index Fund377KUS$955KNo changeJul 31, 2026
Vanguard Emerging Markets Stock Index Fund373KUS$946KNo changeJul 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF224KUS$556KNo changeJun 30, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund93,183US$236KNo changeJul 31, 2026
Vanguard Total World Stock Index Fund32,280US$81,775No changeJul 31, 2026
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF29,844US$73,951No changeJun 30, 2026
State Street(R) SPDR(R) S&P(R) China ETF21,708US$53,790−864Jun 30, 2026
Vanguard ESG International Stock ETF4,984US$14,120No changeMay 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Susan RingdalEVP, Strategic Planning and Global Affairs · Since at least May 27, 2025

Open People

Log in to ask 6ix AI your own questions about Bio-Thera Solutions, Ltd.